Abstract: A photopolymerization initiator which is a compound having a structure in which one or more carbonyl groups that link to a carbon atom are further directly bonded to an aromatic ring of an aromatic acyl group that bonds to a phosphorus atom in an acylphosphine oxide structure. A producing method of a photopolymerization initiator produces the photopolymerization initiator. In a polymerizable composition and an ink jet recording method, the photopolymerization initiator is used. Furthermore, an acylphosphine oxide compound has a partial structure represented by Formula 1 or Formula 2.

Abstract: The present subject matter provides a safe alternative for producing an important intermediate useful for preparing the herbicide glufosinate, without need for chlorine components in the manufacturing process. In particular, a process for preparing alkyl phosphinic aid alkyl ester is provided, including the step of alkylating alkyl phosphinic acid ester in a non-polar solvent in the same apparatus as used to first produce the alkyl phosphinic acid ester, and without isolating the alkyl phosphinic acid ester before the alkylation step is conducted. More specifically, a process is presented for preparing methyl phosphinic acid butyl ester, by alkylating butyl phosphinic acid ester in a non-polar solvent, in the same apparatus as used previously to first produce the butyl phosphinic acid ester and without isolating the butylphosphinic acid ester before alkylation.

Abstract: The invention relates to compounds which correspond to the general formula (I) below: in which: R1 and R2 represent, independently of one another, a C4 to C12 acyclic hydrocarbon group; R3 represents H; a C1 to C12 acyclic hydrocarbon group with optionally one or more heteroatoms; a C5 or C6 cyclic hydrocarbon group; or a 5- or 6-membered heterocyclic group; R4 represents H or a C1 to C12 acyclic hydrocarbon group with optionally one or more heteroatoms; R5 and R6 represent, independently of one another, H; a C1 to C12 acyclic hydrocarbon group with optionally one or more heteroatoms; a C5 or C6 cyclic hydrocarbon group; or a 5- or 6-membered heterocyclic group; on the condition however that R5 and R6 do not each represent H.

Abstract: The present invention provides a phosphorous compound represented by general formula (1), and transition metal complexes containing such phosphorous compounds as ligands: wherein R1 to R7, A, B, Y, and Z have the same meanings as those defined in the specification.

Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.

Abstract: The compounds represented by the following general formula have excellent properties as a charge transport material. In the formula, R1 to R3 represent a substituent, n1 and n2 indicate an integer of from 0 to 5, n3 indicates an integer of from 0 to 4, X represents a linking group of —O—, —S—, —SO2—, —CS—, —R4—, —C(R5)(R6)—, —PO(R7)—, —Si(R8)(R9)—, >PO—, >Si(R10)— or >Si<, m is an integer of from 2 to 4, R4 represents an aliphatic cyclic linking group, and R5 to R10 represent a hydrogen atom, an alkyl group, an aryl group, etc.

Abstract: The 5? and 3?-thiol modified oligonucleotides are attractive tools with a vast number of potential applications in the field of nucleic acid chemistry. There is a strong interest in developing new disulfide compounds or to optimize synthesis of existing disulfide modifiers, which are efficient in generating the 3?- or 5?-end reactive thiol group. Various synthetic protocols have been employed to synthesize pure 3-((3-(bis(4-dimethoxytrityl)propyl)di-sulfanyl)propyl 2-cyanoethyl diisopropylphosphoramidite (compound 2) starting from 3-(dimethoxytrityl)propyl)disulfanyl)pro-pan-1-ol, (compound 1). Herein, we describe an efficient, reproducible synthetic and purification protocol for target compound 2 from the compound 1. It is noteworthy that our reaction conditions were reproducible even at multi-gram scale (27 g) with a purity level as achieved in a small scale.

Abstract: The present invention relates to an organic electronic device, comprising a first electrode, a second electrode, and a substantially organic layer comprising a compound according to formula (I) between the first and the second electrode: wherein A1 is a C6-C20 arylene and each of A2-A3 is independently selected from a C6-C20 aryl, wherein the aryl or arylene may be unsubstituted or substituted with groups comprising C and H or with a further LiO group, provided that the given C count in an aryl or arylene group includes also all substituents present on the said group.

Abstract: Disclosed are methods for making chiral phosphorus ligands including chiral phosphines, chiral phosphine oxides, phosphonamides, and aminophosphines. The chiral phosphorus ligands prepared by the methods of the invention are useful as components of chiral catalysts, e.g., transition metal complexes.

Abstract: An electro lye includes a compound of Formula I or IA: where each instance of R1 is independently H, alkyl, alkoxy, alkenyl, aryl, heteroaryl, or cycloalkyl; each instance of R2 is independently H, alkyl, alkoxy, alkenyl, aryl, heteroaryl, or cycloalkyl; each instance of R3 is independently H, alkyl, alkenyl, aryl, or cycloalkyl; each instance of R4 is independently H, halogen, CN, NO2, phosphate, alkyl, alkenyl, aryl, heteroaryl, or cycloalkyl; x is 1, 2, 3, 4, or 5; y is 1 or 2; and z is 0, 1, 2, 3, or 4.

Abstract: The present invention disclosed a preparation method of parylene AF4, which provides a reactant and a reducing agent with the use of catalyst or exposure to UV light with photo-initiator, to shorten the reaction time as a result of minimized the byproduct(s) formation, and obtain high purity (>99.0%) of parylene AF4 product under high concentrated reaction mixture.

Abstract: Disclosed are methods for making chiral phosphorus ligands including chiral phosphines, chiral phosphine oxides, phosphonamides, and aminophosphines. The chiral phosphorus ligands prepared by the methods of the invention are useful as components of chiral catalysts, e.g., transition metal complexes.

Abstract: The compounds represented by the following general formula have excellent properties as a charge transport material. In the formula, R1 to R3 represent a substituent, n1 and n2 indicate an integer of from 0 to 5, n3 indicates an integer of from 0 to 4, X represents a linking group of —O—, —S—, —SO2—, —CS—, —R4—, —C(R5)(R6)—, —PO(R7)—, —Si(R8)(R9)—, >PO—, >Si(R10)— or >Si<, m is an integer of from 2 to 4, R4 represents an aliphatic cyclic linking group, and R5 to R10 represent a hydrogen atom, an alkyl group, an aryl group, etc.

Abstract: The present invention disclosed a preparation method of parylene AF4, which provides a reactant and a reducing agent with the use of catalyst or exposure to UV light with photo-initiator, to shorten the reaction time as a result of minimized the byproduct(s) formation, and obtain high purity (>99.0%) of parylene AF4 product under high concentrated reaction mixture.

Abstract: Method produces polyprenyl phosphates of formula, where each isoprene unit contains 5 carbon atoms, W is ?-end isoprene, T is trans-isoprene, C is cis-isoprene, S is 2,3-dihydroisoprene, a=0-10, b=0-39, c=0-1, a+b+c=4-40, and X is of formula OPO3MM?, wherein M and M? are identical or different and are a hydrogen cation or monovalent inorganic or organic cation, or M and M? together are divalent inorganic or organic cation, the phosphorylation of the relevant polyprenol or a mixture of oligomer homologues, where X is hydroxyl group, using a substituted ammonium salt of phosphoric acid in presence of condensing agent, is carried out in a medium of first aprotic organic solvent; and a polyprenyl phosphate of mono- or disubstituted salts thereof with monovalent cations or in form of salts thereof with divalent cations is isolated by extraction and precipitation.

Abstract: Amido-fluorophosphite compounds and catalyst systems comprising at least one amido-fluorophosphite ligand compound in combination with a transition metal are described. Moreover, the use of amido-fluorophosphite containing catalysts for transition metal catalyzed processes, especially to the hydroformylation of various olefins to produce aldehydes are also described.

Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: A non-aqueous electrolyte additive for a lithium secondary battery, a non-aqueous electrolyte for a lithium secondary battery, and a lithium secondary battery, the additive including a bidentate phosphorus compound represented by the following Chemical Formula 1.

Abstract: The principal object of the invention is to provide a lithium salt having excellent ion conductivity. The invention solves the problem by providing a lithium salt having a structure represented by the general formula (1): in which “M” represents B, Si, Ge, P, As or Sb; “X” represents the valence of “M”; “R1” represents —CmH2m— whereupon “m” is an integer of 1 to 4; “R2” represents —CkH2k+1 whereupon “k” is an integer of 1 to 8; and “n” represents 0 to 12.

Abstract: This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D3 and (20R)-25-hydroxy-2-methylene-19-nor-vitamin D3, as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. Although these compounds have relatively low calcemic activities they may also be useful in the treatment of bone diseases due to their ability to act as prodrugs in vivo.

Abstract: The invention pertains to an oligomer or polymer substituted by one or more bisacylphosphine oxide moieties, characterized in that said bisacylphosphine oxide moiety is linked via the phosphorous atom, optionally via a spacer group, to the oligomer or polymer backbone; as well as to specifically functionalized bisacylphosphine oxides, suitable to prepare said polymers or oligomers.

Abstract: The synthesis and biochemical utility of modified oligonucleotides containing diphosphodiester internucleotide linkages. The synthesis of these compounds was carried out using diphosphitylating reagents. Oligonucleotides containing diphosphate diester bridges wherein said oligonucleotides are synthesized via a solid-phase synthesis strategy to form modified oligonucleotides. Diphosphitylating, triphosphitylating, tetraphosphitylating, ?-triphosphitylating, bifunctional diphosphitylating, bifunctional triphosphitylating, and bifunctional tetraphosphitylating reagents wherein, the phosphorus atoms are linked together through oxygen, sulfur, amino, or methylene groups and/or are substituted with chlorine, diisopropylamine and cyanoethoxy groups.

Abstract: A process for the preparation of a polymer nanoparticle by a photoinduced emulsion polymerization includes preparing an emulsion comprising at least one surfactant, a dispersed phase and a continuous phase. The dispersed phase comprises at least one polymerizable monomer and the continuous phase comprises water and at least one photoinitiator. The at least one polymerizable monomer is polymerized by exposing the emulsion to an electromagnetic radiation having a wavelength so as to induce a generation of radicals from the at least one photoinitiator.

Abstract: The present invention relates to compounds of formula wherein the residues have various meanings and their use as pharmaceuticals.

Abstract: Provided herein are ruthenium complexes of Formula (I), and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: The present invention provides an anti-wear compound selected from phosphorus compounds as represented by the following General Formula (2) or metal salts thereof as represented by the following General Formula (3).

Abstract: A process for producing a compound of the formula: including reacting of a compound of the formula: with diphenyl phosphine oxide using a binary phase reaction mixture including diphenyl phosphine oxide in an organic solvent, a basic aqueous solution, and a phase transfer catalyst, to obtain the compound of formula 1, wherein Ph is phenyl, X1 and X2 are both hydrogen or X1 and X2 taken together are CH2, R1 is a protecting group, R2 is fluorine, hydrogen, or OR3, wherein R3 is a protecting group, and the squiggly line represents a bond that results in the adjacent double bond being in either the E or Z configuration, is disclosed.

Abstract: [Problem to be Solved] To provide an axially asymmetric optically active biarylphosphorus compound that can easily produced without the step of optical resolution which was almost indispensable in conventional methods. [Means for Solving the Problems] A method for producing an axially asymmetric phosphorus compound represented by the general formula (1), comprising a cycloaddition reaction of a compound having a triple bond with the use of a catalyst containing rhodium metal and an optically active bisphosphine. (In the formula (1), R1 and R2 may be the same or different and independently are an alkyl group optionally having a substituent group, a cycloalkyl group optionally having a substituent group, an aryl group optionally having a substituent group, an alkoxy group optionally having a substituent group or an aryloxy group optionally having a substituent group; * is axial asymmetry.

Abstract: A specific culture medium for growth, detection, identification and/or counting of Staphylococcus aureus bacteria, said medium includes at least one fluorogenic, chromogenic or luminescent substrate of phospholipase C. Said medium permits differentiation between Staphylococcus aureus and coagulase-negative staphylococci.

Abstract: Compounds of the formula (I), in the form of mixtures comprising predominantly one diastereomer or in the form of pure diastereomers, Z1-Q-P*R0R1 (I) in which Z1 is a C-bonded, secondary phosphine group —P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals, or Z1 is the —P*R0R1 group; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton, and in which base skeletons a secondary phosphine group Z1 is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group, and in which base skeletons a P-chiral group —P*R0R1 is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group to a carbon atom such that the phosphorus atoms are linked via 1 to 7 atoms of a carbon chain optionally i

Abstract: Compounds of the formula I, in the form of mixtures comprising predominantly one enantiomer or in the form of pure enantiomers, secondary phosphine-Q-P*(?O)HR1 (I) in which secondary phosphine is a C-bonded, secondary phosphine group —P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton, and in which base skeletons a secondary phosphine group is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group, and in which base skeletons a P-chiral group —P*(O)HR1 is bonded to a carbon atom such that the phosphorus atoms are linked via 1 to 7 atoms of a carbon chain optionally interrupted by heteroatoms from the group of O, S, N, Fe or Si; P* is a chiral phosphorus atom; and R1 is a hydrocarbon radi

Abstract: This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.

Abstract: The present invention relates to oligomeric or polymer dithiophosphate di- or poly-sulfides and their utility in rubbers. Another aspect of the invention is a method for making oligomeric or polymeric dithiophosphates by reacting phosphorous pentasulfide with a di- or polyol and a mono alcohol to produce a dithiophosphoric acid, and then oxidizing the dithiophosphoric acid with an oxidizing agent to produce an oligomeric or polymeric dithiophosphate.

Abstract: The invention disclosed a total synthesis process of novel ethoxy combretastatins and their prodrugs. Combretastatins are chemically modified by ethoxy substituted on the 4?-position of their B aryl ring and are converted to be their soluble prodrugs of phosphate or their inner salt of phosphorylcholine by modifying the hydroxyl on the 3?-position of their B aryl ring. Similarly, 3?-amino combretastatin is 4?-ethoxy chemically modified and further side chain of amino acid can be introduced to the amino to form soluble prodrug of amino acidamide. The structure of the said compound is showed as formula (I). Ethoxy combretastatins possess potent tubulin polymerization inhibitory activity and can be used for the treatment of inhibiting tumor or neovascular.

Abstract: This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.

Abstract: Disclosed is a novel asymmetric ligand which can be synthesized by a short process at low cost and is capable of exhibiting higher catalytic activity and enantioselectivity than the conventional ligands derived from sugars. Also disclosed are a method for producing such an asymmetric ligand, and a catalyst using such an asymmetric ligand. Specifically disclosed is a ligand represented by the general formula I below or the like. (In the formula, R1 and R2 independently represent 0-5 substituents; X represents P, As or N; m represents an integer of 0-7; n represents an integer of 0-3; A1-A4 independently represent hydrogen, fluorine, chlorine, bromine, benzoyl or acetyl, or alternatively A2 and A3 combine together to form a ring.

Abstract: A molecular probe for labeling myelin includes a fluorescent stilbenzene derivative.

Abstract: The invention relates to carboxylic acid derivates which contain at least one organically polymerisable group and at least one group which contains phosphorous and is reactive or that modulates the properties of the molecule. The invention also relates to a method for production of the inventive molecules and the use thereof in dentistry and for influencing the properties of materials.

Abstract: The invention concerns novel phosphonate derivatives, preparation method, use thereof as ligands modulating T ?9?2 lymphocyte activity and pharmaceutical compositions comprising them.

Abstract: An amino or thiol linker building block for the synthesis of amino or thiol functionalized amino acids and generally of the following structure: is provided. Such building block may be introduced in the 5? end position of an amino acid under standard coupling conditions. Such building block allows in-line coupling control, “trityl-on” purification, and solid support functionalization/derivatization. Such building block is a stable, solid compound and can therefore be easily handled. With the building block of the present invention, deprotection may be carried out under standard detritylation conditions.

Abstract: A novel process for preparing in a high purity and in a high yield phosphonates having a secondary and/or tertiary alcoholic hydroxyl group at the end of a P—C bond chain thereof with the use of a phosphite and a carbonyl compound as raw materials.

Abstract: The invention relates to alkylphosphonous acids, salts and esters of formula (I) A-P(?O)(OX)—H (I) wherein A is C2-C20alkyl, C2-C20alkylene, and C8-C20 alkaryl are optionally substituted, and X is H, alkyl, aryl, alkylaryl, alkenyl, substituted alkyl, aryl, alkaryl, alkenyl, ammonium, primary, secondary, tertiary, quaternary alkyl and/or aryl ammonium, an alkali metal, an alkaline earth metal, a metal of the third and fourth main group and the second, fourth and eight sub-group or a metal of the lanthanoid group. The invention also relates to methods for producing same and to the uses of said compounds.

Abstract: Disclosed is a process for producing an optically active phosphorus compound having an R- or S-type absolute configuration on phosphorus in a simple manner and at high efficiency, while avoiding racemization. An optically active phosphorus compound having an R- or S-type absolute configuration on phosphorus represented by the general formula (III) can be produced by reacting an optically active phosphorus compound having an R- or S-type absolute configuration on phosphorus represented by the general formula (I) with a metal compound represented by the general formula (II) and water. (I) wherein R1 represents a hydrogen atom, analkyl group, a cycloalkyl group, an aralkyl group or an aryl group; and R2 represents a hydrogen, an alkyl group, a cycloalkyl group, an aryl group, an aralkyl group, alkenyl group, an alkoxy group, an aryloxy group, a heterocyclic ring residue or a silyl-containing group. R3M (II) wherein R3 is the same as R2; and M represents a lithium or magnesium halide MgX (X?Cl, Br or I).

Abstract: Processes for preparing (E)-2,4,6-(Trimethoxystyryl)-3-O-Phosphate Disodium-4-Methoxybenzyl Sulfones and uses thereof as antiproliferative agents, including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

Abstract: Small molecule bradykinin inhibitor bisphosphonate amide derivatives useful for inhibiting cancer growth and treating cancer residing in and around bone are disclosed. These compounds and pharmaceutical compositions containing these compounds are particularly useful for the treatment of prostate cancer bone metastases.

Abstract: A mutual prodrug of an AISTM and a ?-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 ?L) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between about 1 to 5?, produced by nebulization or by dry powder inhaler.

Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Abstract: Process for the preparation of substituted pyridine derivatives of formula (I) comprising reaction of a ?-?-unsaturated carbonyl compound of formula (II) R3—C(O)—C(R1)?C(R2)-G with a Wittig reagent or Horner-Wadsworth-Emmons reagent in the presence of a base and optionally subsequent cyclization.

Abstract: The invention relates to a process for the preparation of (bis)acylphosphanes of formula I, wherein n and m are each independently of the other 1 or 2; R1 if n=1, is e.g. unsubstituted or substituted C1-C18alkyl or C2-C18alkenyl, or phenyl, R1 if n=2, is e.g. a divalent radical of the monovalent radical defined above; R2 is e.g. C1-C18alkyl, C3-C12cycloalkyl, C2-C18alkenyl, mesityl, phenyl, naphthyl; R3 is one of the radicals defined under R1; the process comprises the steps a) contacting e.g.

Abstract: The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.